Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis - Related Studies

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

This study has been completed.

Study NCT00001646. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Acquired Immunodeficiency Syndrome
		Aspergillosis
		HIV Infections
		Immunologic Deficiency Syndromes
		Neutropenia

2	Additional conditions recognized in this trial
		Infection
		Syndrome

3	More general conditions related to this trial
		Agranulocytosis
		Disease
		Hematologic Diseases
		Immune System Diseases
		Lentivirus Infections
		Leukocyte Disorders
		Leukopenia
		Mycoses
		Pathologic Processes
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Voriconazole
		Amphotericin B

5	Additional drug interventions recognized in this trial
		Abelcet
		AmBisome

6	More general drug interventions related to this trial
		Amebicides
		Anti-Bacterial Agents
		Anti-Infective Agents
		Antibiotics, Antifungal
		Antifungal Agents
		Antiparasitic Agents
		Antiprotozoal Agents
		Pharmacologic Actions
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)